Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.35 |
| ▸ | CA1 | P00915 | 5/20 | 0.35 |
| ▸ | MMP1 | P03956 | 3/20 | 0.35 |
| ▸ | MMP2 | P08253 | 3/20 | 0.35 |
| ▸ | MMP9 | P14780 | 3/20 | 0.35 |
| ▸ | MMP8 | P22894 | 3/20 | 0.35 |
| ▸ | MMP13 | P45452 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 4/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL5489255 | 0.98 | CA2 (0.34) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL5487823 | 0.91 | CA2 (0.41) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL17469885 | 0.91 | CA2 (0.36) | CA2CA1CA9TSHRTDP1 | |
| SCHEMBL17469880 | 0.91 | CA2 (0.36) | CA2CA1CA9TSHRTDP1 | |
| Ammonia Solution, Strong SCHEMBL5491551 | 0.90 | CA2 (0.39) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL18632022 | 0.86 | CA2 (0.36) | CA2CA1CA9TSHRTDP1 | |
| SCHEMBL17469735 | 0.85 | CA2 (0.39) | CA2CA1CA9TSHRTDP1 | |
| SCHEMBL17456448 | 0.84 | CA1 (0.34) | CA2CA1CA9TSHRTDP1 | |
| SCHEMBL17456378 | 0.83 | CA2 (0.37) | CA2CA1CA9TSHRTDP1 | |
| SCHEMBL17466292 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219379-A1 | Ionic Liquid and Process for Producing the Same | KANEKA CORPORATION (JP) | 2007-09-20 | — | — | US | disclosed |
| CN-1653641-A | Nonaqueous electrolyte and lithium secondary battery using the same | MITSUBISHI CHEM CORP (JP) | 2005-08-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219379-A1 | Ionic Liquid and Process for Producing the Same | HCN4, HCN2, HCN3 | CA2 766/4885CA1 2585/4885MMP1 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.